Home ProductsMedical Raw Materials

98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceutical Raw Materials

Good quality Pharma Raw Material for sales
Good quality Pharma Raw Material for sales
I'm Online Chat Now

98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceutical Raw Materials

China 98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceutical Raw Materials supplier

Large Image :  98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceutical Raw Materials

Product Details:

Place of Origin: China
Brand Name: PooChun
Certification: ISO9001 SGS HACCP
Model Number: 98319-26-7

Payment & Shipping Terms:

Minimum Order Quantity: Negotiable
Price: Negotiable
Packaging Details: 1~10 kg / Al-Pt bag,10kg / 25kg fiber drum
Delivery Time: 1-3days after payment
Payment Terms: T/T, L/C
Supply Ability: 100 ton per Month
Contact Now
Detailed Product Description
CAS: 98319-26-7 MF: C23H36N2O2
Shipping: DHL TNT FedEx HKEMS UPS Use: Prostate Enlargement, Pattern Hair Loss
Appearance: White Powder Type: The Treatment Of Benign Prostatic Hyperplasia ( Enlarged Prostate ) And Male Pattern Hair Loss
High Light:

steroid hormones


pharmaceutical intermediates

Finasteride Medicine Raw Material Finasteride For Transgender women Excessive hair growth




Finasteride, also known as 17β-( N - tert - butylcarbamoyl )- 4- aza - 5α - androst - 1 - en - 3 - one, is a synthetic androstane steroid and 4 - azasteroid. It is an analogue of androgen steroid hormones like testosterone and DHT.


Finasteride is a lipophilic compound.



Society and culture


The Food and Drug Administration advises that donation of blood or plasma be deferred for at least one month after taking the last dose of finasteride.

Harold Bornstein, Donald Trump's personal physician, stated Trump was taking finasteride to promote hair growth.




From 2005 to 2009, the World Anti - Doping Agency banned finasteride because it was discovered that the drug could be used to mask steroid abuse. It was removed from the list effective January 1, 2009, after improvements in testing methods made the ban unnecessary. Athletes who used finasteride and were banned from international competition include skeleton racer Zach Lund, bobsledder Sebastien Gattuso, footballer Romário and ice hockey goaltender José Théodore.


Brand names

Drug trade names include Propecia, marketed for male pattern baldness ( MPB ), and Proscar, for benign prostatic hyperplasia ( BPH ); both are products of Merck & Co. There is 1 mg of finasteride in Propecia and 5 mg in Proscar. Merck's patent on finasteride for the treatment of BPH expired on June 19, 2006. Merck was awarded a separate patent for the use of finasteride to treat MPB. This patent expired in November 2013.



Men in the US and Canada concerned about persistent sexual side effects "coined the phrase 'post finasteride syndrome', which they say is characterized by sexual, neurological, hormonal and psychological side effects that can persist in men who have taken finasteride for hair loss or an enlarged prostate". In 2012, a health advocacy group called the Post - Finasteride Syndrome Foundation was formed with the primary goal of finding a cure for the reported syndrome and a secondary goal of raising awareness. According to the company's 1Q2016 financial filing, Merck is a defendant in 1,385 product liability lawsuits which have been filed by customers alleging they have experienced persistent sexual side effects following cessation of treatment with finasteride.





Sexual dysfunction


Whether finasteride causes long - term sexual dysfunction in some men after stopping drug treatment is unclear. There are case reports of persistent diminished libido or erectile dysfunction after stopping the drug and the FDA has updated the label to inform people of these reports. A 2010 review found moderate quality evidence that finasteride increased the risk of sexual dysfunction, but not that people stopped using it because of sexual side effects.


When finasteride was originally approved for hair loss in 1997, the FDA approval review reported that it appears well tolerated, with the most common side effects being related to sexual function. In many people these side effects resolve if the medication is stopped and occasionally resolve even if the medication is continued. They additionally state " the sexual functioning questionnaire seems to have given a sensitive reflection of the disturbance on sexual functioning ".


A meta - analysis and systematic review found that sexual dysfunction, including erectile dysfunction, loss of libido, and reduced ejaculate, may occur in 3.4 to 15.8% of men treated with finasteride or dutasteride. This is linked to lower quality of life and can cause stress in relationships. There is also an association with lowered sexual desire. It has been reported that in a subset of men, these adverse sexual side effects may persist even after discontinuation of finasteride or dutasteride.





Test Items Specification Test Results
Description White or off-white crystalline powder Off-white crystalline powder
Specific rotation -56°~-60° -58.2°
Identification IR Matches with working standard Complies
Solubility Freely soluble in chloroform and in alcohol;
Very slightly soluble in water
Heavy metals ≤10ppm <10ppm
Water ≤0.3% 0.22%
Residue on ignition ≤0.1% 0.05%
Relative material Maximum impurities≤0.5% 0.36%
Total impurities≤1.0% 0.52%
Assay 98.5~101.0% 99.59%
Conclusion The specification conform with Enterprise standard



98319-26-7 Finasteride For Transgender Women Excessive Hair Growth , Pharmaceutical Raw Materials

Contact Details
Shanghai Poochun Industry Co.,Ltd

Send your inquiry directly to us (0 / 3000)